Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28805112 | 0.83 | LMNA (0.57) | TSHRMAPTPDCD1CD274NPC1 | |
| SCHEMBL6311599 | 0.80 | TSHR (0.61) | TSHRMAPTNPC1RAB9AALDH1A1 | |
| Benzoic Acid 1-Methylethyl Ester SCHEMBL96918 | 0.79 | PDCD1 (0.78) | TSHRMAPTPDCD1CD274NPC1 | |
| Benzoic Acid 1-Methylethyl Ester SCHEMBL27592410 | 0.79 | PDCD1 (0.78) | TSHRMAPTPDCD1CD274NPC1 | |
| SCHEMBL13445453 | 0.79 | NPC1 (0.60) | TSHRNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL20576070 | 0.79 | RAB9A (0.56) | TSHRNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL9505665 | 0.78 | TDP1 (0.57) | TSHRNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL8773117 | 0.78 | TDP1 (0.57) | TSHRNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL20168302 | 0.78 | PDCD1 (0.51) | TSHRMAPTPDCD1CD274NPC1 | |
| SCHEMBL5082895 | 0.78 | PDCD1 (0.56) | TSHRMAPTPDCD1CD274NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | TSHR 3946/4885MAPT 4568/4885PDCD1 4395/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | TSHR 3165/4885MAPT 4598/4885PDCD1 4037/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | TSHR 3333/4885MAPT 4532/4885PDCD1 4436/4885 |
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | TPI1, HPGDS, GPI | TSHR 3165/4885MAPT 4598/4885PDCD1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.